🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

18,91 USD

Máx. histórico

48,47

1806 días

Caída desde máximo

-60,99%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+5,94%

Cierre anterior

17,85

Rango de hoy

18,05 – 18,98

Volumen hoy

1.935.563

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,63%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 1 día
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
20/09/2018 14,09 14,40 13,74 13,87 -1,07% 4,68% 140.400
19/09/2018 13,49 14,08 13,03 14,02 +5,26% 7,82% 87.400
18/09/2018 13,05 13,52 12,89 13,32 +2,94% 4,83% 81.700
17/09/2018 14,10 14,11 12,78 12,94 -8,42% 9,43% 97.700
14/09/2018 14,19 14,83 14,01 14,13 -0,42% 5,78% 67.000
13/09/2018 13,23 14,48 13,23 14,19 +7,66% 9,45% 151.700
12/09/2018 13,38 13,63 13,10 13,18 -1,64% 3,96% 118.800
11/09/2018 12,98 13,65 12,91 13,40 +3,16% 5,74% 44.600
10/09/2018 13,05 13,30 12,78 12,99 +1,09% 3,98% 67.400
07/09/2018 13,03 13,27 12,75 12,85 -1,61% 3,99% 46.300
06/09/2018 13,12 13,22 12,90 13,06 -0,23% 2,44% 161.500
05/09/2018 14,25 14,57 13,02 13,09 -9,54% 10,88% 138.500
04/09/2018 14,34 14,51 13,97 14,47 +0,49% 3,76% 43.100
31/08/2018 14,47 14,88 14,27 14,40 -0,48% 4,24% 82.100
30/08/2018 14,09 14,99 14,00 14,47 +3,88% 7,03% 60.000
29/08/2018 15,00 15,00 13,78 13,93 -6,45% 8,13% 141.400
28/08/2018 15,00 16,06 14,80 14,89 -0,40% 8,40% 275.400
27/08/2018 13,55 15,00 13,55 14,95 +10,91% 10,70% 142.100
24/08/2018 13,50 13,74 13,05 13,48 +0,00% 5,11% 125.600
23/08/2018 13,70 13,78 13,20 13,48 -1,17% 4,23% 40.600
22/08/2018 13,69 13,78 13,14 13,64 +1,04% 4,68% 55.700
21/08/2018 13,08 13,51 13,08 13,50 +3,05% 3,29% 56.600
20/08/2018 13,36 13,54 12,91 13,10 -1,28% 4,72% 28.500
17/08/2018 13,31 13,43 13,07 13,27 +0,76% 2,70% 45.400
16/08/2018 13,10 13,30 12,68 13,17 +1,54% 4,76% 82.300
15/08/2018 12,25 13,25 12,25 12,97 +5,53% 8,16% 228.800
14/08/2018 11,95 12,68 11,95 12,29 +3,80% 6,11% 69.700
13/08/2018 11,80 12,05 11,54 11,84 +0,08% 4,33% 42.700
10/08/2018 11,84 12,11 11,77 11,83 -0,84% 2,87% 34.100
09/08/2018 11,55 12,12 11,25 11,93 +3,56% 7,53% 52.100